Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh · Delayed Price · Currency is BDT 57.50
-0.60 (-1.03%)
At close: Apr 13, 2026
Navana Pharmaceuticals Revenue
Navana Pharmaceuticals had revenue of 2.78B BDT in the quarter ending December 31, 2025, with 24.83% growth. This brings the company's revenue in the last twelve months to 10.07B, up 26.26% year-over-year. In the fiscal year ending June 30, 2025, Navana Pharmaceuticals had annual revenue of 8.84B with 28.19% growth.
Revenue (ttm)
10.07B
Revenue Growth
+26.26%
P/S Ratio
0.61
Revenue / Employee
2.10M
Employees
4,798
Market Cap
6.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 8.84B | 1.94B | 28.19% |
| Jun 30, 2024 | 6.90B | 1.19B | 20.89% |
| Jun 30, 2023 | 5.71B | 947.45M | 19.91% |
| Jun 30, 2022 | 4.76B | 1.15B | 31.95% |
| Jun 30, 2021 | 3.61B | 457.57M | 14.53% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The ACME Laboratories | 38.86B |
| Beacon Pharmaceuticals | 14.78B |
| The IBN SINA Pharmaceutical Industry | 13.42B |
| Techno Drugs | 3.15B |
| Orion Pharma | 3.12B |
| Asiatic Laboratories | 2.24B |
| Pharma Aids | 474.48M |
| Silco Pharmaceuticals | 431.04M |